Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

Analysis of 35,213 patients with stage II-III colon cancer revealed that recurrence risk drops below 0.5% at 6 years post-surgery, supporting a practical definition of cure. Women showed a ...

Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical ...

Defining cure in stage II and III colon cancer has been challenging, and has never been systematically studied. In an analysis of 15 randomized trials, colon cancer relapse risk fell to 0.5% by year 6 ...

ctDNA testing post-surgery identifies high-risk stage 3 colon cancer patients more accurately than traditional staging methods. Detectable ctDNA correlates with a four- to six-fold increased risk of ...

Gut microbiome dysbiosis is known to play a role in colorectal cancer (CRC) development and progression. Now, a prospective observational cohort study provides insights into the role of the intestinal ...

A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. The research, involving over ...

Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti–programmed death ligand 1 agent) to a ...